Treatment and outcome of children with relapsed ependymoma: A multi-institutional retrospective analysis

Stergios Zacharoulis, Sue Ashley, Lucas Moreno, Jean Claude Gentet, Maura Massimino, Didier Frappaz

Research output: Contribution to journalArticlepeer-review


Introduction More than a third of children with ependymoma experience relapse, and despite multimodal treatment, less than 25% of them can then achieve long-term survival. Prognostic factors for patients who relapse have not been extensively analyzed. Patients and methods We retrospectively analyzed 82 patients from four pediatric oncology European institutions in order to identify prognostic factors and influence of treatment modalities in relapsed ependymoma. Results First relapse occurred after a median of 19 months (1 month-16 years). Five-year progression-free survival and overall survival of the cohort were 17% and 27.6%, respectively. Survival was statistically significantly higher for patients achieving gross total resection. No survival benefit was seen for children receiving chemotherapy whereas patients who were amenable to some form of reirradiation had a better outcome. Objective responses were found in more than 25% of patients receiving oral etoposide, temozolomide, or vincristine/etoposide/cyclophosphamide regimens. Multivariate analysis confirmed that patients with mixed relapses, no surgery at relapse, and receiving chemotherapy did worse (hazard ratio=3.6, 3.3, and 1.7, respectively, all p

Original languageEnglish
Pages (from-to)905-911
Number of pages7
JournalChild's Nervous System
Issue number7
Publication statusPublished - Jul 2010


  • Re-irradiation
  • Relapsed ependymoma
  • Targeted therapies

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Clinical Neurology


Dive into the research topics of 'Treatment and outcome of children with relapsed ependymoma: A multi-institutional retrospective analysis'. Together they form a unique fingerprint.

Cite this